Life sciences company Azenta (NASDAQ: AZTA) fell short of the market’s revenue expectations in Q2 CY2025, with sales flat year on year at $143.9 million. Its non-GAAP profit of $0.14 per share was in line with analysts’ consensus estimates.

Is now the time to buy AZTA? Find out in our full research report (it’s free).

StockStory’s Take

Azenta’s Q2 results were met with a significant negative market reaction following a flat sales performance that missed Wall Street’s revenue expectations. Management attributed the lack of growth to persistent macroeconomic pressures and delayed customer purchasing decisions, particularly in its core product lines. CEO John Marotta described the environment as one of "funding constraints, supply chain complexities or market uncertainties," with growth primarily coming from next-generation sequencing and sample storage. Despite these headwinds, the company demonstrated operational improvements, reflected in higher adjusted EBITDA margins and reduced general and administrative costs.

Looking forward, Azenta’s guidance remains underpinned by expectations for a recovery in customer demand and continued operational discipline. Management is counting on a robust sales funnel and ongoing investments in R&D, product management, and commercial capabilities to drive growth. CFO Lawrence Lin highlighted "momentum in NGS stores" and improved "on-time delivery" as reasons for confidence in future quarters, though he acknowledged execution risk remains. The company plans to maintain its focus on margin expansion and organic growth, while keeping an eye on potential strategic M&A opportunities to supplement its core business.

Key Insights from Management’s Remarks

Azenta’s management credited its margin improvement to a combination of product mix, operational efficiency, and focused resource allocation, while acknowledging order delays and funding uncertainty as major headwinds.

• Product mix shifts: The company saw stronger performance in next-generation sequencing, sample storage, and product services, while core product lines lagged due to delayed customer purchases and capital spending constraints, especially among pharma clients.
• Operational turnaround efforts: Margin expansion was driven by cost discipline and structural realignment, with notable reductions in general and administrative expenses and redeployment of resources to customer-facing functions.
• Regional commercial model: Azenta implemented new sales leadership and a shift toward regionally focused commercial teams, aiming for better alignment with customer needs and swifter response to market changes.
• R&D and product management investments: Management increased funding for R&D and product management, emphasizing a renewed focus on customer-driven innovation and development of new solutions, particularly in automation and biorepository services.
• Customer engagement and feedback: Ongoing direct outreach to customers was highlighted as a tool for real-time market intelligence, enabling faster adaptation to shifting demand and helping to identify outsourcing opportunities as clients seek to control costs.

Drivers of Future Performance

Azenta’s near-term outlook is shaped by expectations for improved order conversion, margin expansion, and sustained investment in growth initiatives amid continued external headwinds.

• Backlog-driven revenue step-up: Management expects a significant revenue increase in the next quarter, based on a robust backlog and pent-up demand, particularly in sample management and next-generation sequencing product lines. Order pushouts from the current period are anticipated to convert into sales, contingent on customer budget cycles and internal alignment.
• Margin expansion focus: The company plans to sustain adjusted EBITDA margin improvements through ongoing cost controls, operational efficiencies from the Azenta Business System, and a more favorable sales mix. Margin gains are also expected from improvements in gross margin productivity and restructuring benefits.
• Strategic M&A and investment: Azenta remains focused on small, strategic acquisitions closely related to its core areas of automation and biorepository services, aiming for both revenue and margin accretion. Management also signaled continued investment in R&D and commercial capabilities to support organic growth, while monitoring funding and policy changes that could affect customer spending.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will be watching (1) the pace of order conversion from backlog and the resolution of delayed customer purchases, (2) the impact of ongoing investments in R&D and commercial leadership on both revenue growth and margin performance, and (3) signs of stabilization or improvement in funding environments for life sciences customers. Progress on strategic M&A and continued cost discipline will also be key indicators of execution.

Azenta currently trades at $30.99, down from $32.41 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).

Stocks That Trumped Tariffs

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.